Stay current on the most consequential developments in health and medicine — delivered to your inbox each weekday through STAT's complimentary Morning Rounds newsletter. Register here.
Who needs the basketball court when the arena of scientific discovery delivers its own brand of high-stakes competition? Round two of STAT's annual tournament spotlighting breakthroughs in science and medicine is now underway — submit your votes here.
Regulatory upheaval deepens as Prasad departs the FDA once more
Vinay Prasad's tenure at the Food and Drug Administration has come to a contentious close for the second time under the Trump administration, concluding a deeply polarizing chapter as director of the Center for Biological Evaluation and Research — an appointment that itself had been interrupted when he was dismissed in July of last year, only to be reinstated weeks afterward. STAT's Lizzy Lawrence has full coverage of his impending departure, while STAT's Matthew Herper examines five defining lessons from his time at the helm.
Equally significant is Lizzy's in-depth investigation into how the dramatic reduction in public advisory committee convening — a cornerstone of transparent regulatory science — has left rare disease patient advocates deeply alarmed in the wake of a string of unexpected drug rejections attributed to Prasad's leadership.
Over the course of the Trump administration, the frequency of advisory committee meetings evaluating drug applications plummeted by 72%. "Advisory committees are costly," a senior FDA official acknowledged to journalists. "Advisory committees are slow." The remarks underscore a broader philosophical tension between regulatory efficiency and the kind of deliberative, expert-driven oversight that has historically underpinned public confidence in the agency's decision-making framework.
New analysis projects generic semaglutide manufacturing costs as low as $28 annually
Downward pricing pressure on GLP-1 receptor agonists is gaining momentum, with Novo Nordisk announcing it will slash list prices for both Ozempic and Wegovy to $675 — representing roughly half their current price points — in the coming year, with direct-to-consumer channels offering even steeper discounts. Despite this trajectory, semaglutide-based therapies remain financially inaccessible for a substantial portion of patients across the United States and internationally.
A newly published analysis projects that, as patent protections begin expiring — starting this month across markets including India, China, Canada, Brazil, and Turkey — generic formulations could be manufactured for as little as $28 per patient annually. Researchers contend this cost floor could translate into transformative access improvements for individuals managing obesity and type 2 diabetes who have been systematically priced out of these evidence-backed interventions. Ed Silverman reports on the full scope of the findings and their implications for global pharmaceutical pricing dynamics.
The insurance coverage gap driving parents to pursue autism diagnoses
Rising rates of autism spectrum disorder diagnoses across the United States have prompted pediatrician Lawrence Diller to argue that the underlying driver may be fundamentally economic — in short, to "follow the money."
At the center of this dynamic is applied behavioral analysis, or ABA — an evidence-based intervention demonstrably effective not only for young children on the autism spectrum but also for those presenting with conditions such as global developmental delays. The structural barrier: insurers are mandated to cover ABA services exclusively when a child meets formal autism diagnostic criteria, leaving families of children with comparable but differently categorized conditions to absorb costs that can reach $70,000 out of pocket for a single year of treatment.
"The only viable path to ending this desperate pursuit of an autism diagnosis is to extend financial support and therapeutic services to all developmental conditions affecting toddlers and preschoolers," Diller argues. Read his full analysis.
Oregon communities mobilize against private equity's expanding grip on emergency medicine
A pioneering Oregon statute enacted last summer was specifically designed to curtail the accelerating consolidation of healthcare institutions under corporate and private equity ownership. That legislative framework is now facing its first significant stress test, as hospital operator PeaceHealth moves to displace a longstanding local physician group from its emergency department staffing in favor of Atlanta-headquartered ApolloMD — a decision that has ignited community-wide protests and formal petition drives.
"They assumed we would simply acquiesce to the corporate seizure of our livelihoods," one affected local physician told reporter Tara Bannow. The broader industry context amplifies the stakes: nationally, physician-majority-owned groups now handle fewer than half of all emergency department visits, with only one in three encounters managed by hospital-employed physicians directly. Tara's full report chronicles how an alliance of physicians, nurses, and community stakeholders is mounting a coordinated resistance to this consolidation trend.
Contextualizing risk data to strengthen patient decision-making
Imagine your physician informs you that your individual probability of developing a particular cancer type stands at 6% — and that a preventive medication exists to meaningfully reduce that risk. Would you elect to take it?
For most patients, that determination is nearly impossible to make responsibly in the absence of comparative reference points. Learning, for instance, that the population-level baseline risk sits at 3% could substantially shift your calculus toward pursuing pharmacological intervention.
This scenario anchors a JAMA Insights piece published last week examining how clinicians can deploy numerical benchmarking to enhance patients' capacity to weigh the tradeoffs of various clinical pathways. Rather than confining the conversation to a patient's individual risk profile or a single recommended course of treatment, the study's authors propose that presenting comparative statistical context measurably increases patient confidence in — and adherence to — clinical recommendations.
Further reading
- Could a 'living drug' represent the next frontier in treating autoimmune disease? The New Yorker
- Normalizing 72,000 overdose fatalities annually is not an acceptable public health outcome, STAT
- Cardiovascular disease is claiming more young women's lives — and critical warning signs continue to go unrecognized, Vox
- In attempting to sidestep controversy, the FDA generates a new firestorm with its actions against UniQure, STAT
- From disruptive alarms to measured alerts: next-generation firehouse dispatch systems prioritize responder wellbeing, AP